November 29, 2016
Authored and Edited by Hazel Ford, Ph.D.; Adriana L. Burgy
In a move that has surprised many, the UK government has announced that it is pressing ahead with its preparations to ratify the Unified Patent Court Agreement (UPCA).
The UPCA is an agreement between most of the European Union member states to establish a single patent right covering those member states (the Unitary Patent, UP), and a new, centralized court (the Unified Patent Court, UPC) ,which will eventually have sole jurisdiction to decide on disputes arising from both Unitary Patents and European patents in those member states. One of the branches of the Central Division of the UPC is to be located in London, handling most cases relating to the validity of patents in the life sciences and chemistry areas.
The UPCA has been in limbo since the result of the UK’s referendum in June, stating that the UK should leave the European Union (“Brexit”). The UPCA requires ratification by at least 13 participating member states (11 have ratified to date), including France (which has already ratified), Germany, and the UK in order to come into force. Many had assumed that in view of the referendum result, the UK government would be unwilling to proceed with ratification of the UPCA.
The new announcement from the UK Minister of State for Intellectual Property, Baroness Neville Rolfe can be found here. It explains that the UK will continue with its preparations to ratify the Agreement over the coming months and will be working with the Preparatory Committee to bring the UPC into operation as soon as possible.
Questions still remain over the UK’s continuing role in the UPC and Unitary Patent systems when the UK leaves the EU. This announcement, however, indicates the UK’s willingness to participate in the system, and if the UK does proceed with ratification as indicated, and Germany also proceeds with ratification, then the UPC and Unitary Patent could come into effect as early as mid-2017.
For further information about the UPC and Unitary Patent, please visit the dedicated area of our website here.
Copyright © 2016 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
At the PTAB Blog
Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a
§ 325(d) EPR Denial
May 28, 2026
At the PTAB Blog
May 20, 2026
Conference
19th Annual Forum on Pharma & Biotech Patent Litigation in Europe
May 19-20, 2026
Amsterdam
Webinar
Changes at the PTAB from Settled Expectations to Real Parties in Interest to Director Involvement
May 18, 2026
Webinar
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.